Beyond oncology: Selinexor's journey into anti-inflammatory treatment and long-term management

Area of Science:

• Pharmacology
• Immunology
• Oncology

Background:

• Selinexor is a selective inhibitor of nuclear export (SINE) with established anti-tumor activity.
• Emerging evidence suggests Selinexor possesses significant anti-inflammatory properties.

Purpose of the Study:

• To review the dual therapeutic potential of Selinexor in both oncology and inflammatory conditions.
• To elucidate the mechanisms underlying Selinexor's anti-inflammatory effects.
• To highlight the need for further research into its broader clinical applications.

Main Methods:

• Literature review of preclinical and clinical studies on Selinexor.
• Analysis of Selinexor's impact on key inflammatory pathways.
• Evaluation of its efficacy in various cancer types and inflammatory diseases.

Main Results:

• Selinexor demonstrates anti-tumor efficacy in hematologic malignancies and solid tumors, including drug-resistant cases.
• Selinexor exhibits anti-inflammatory effects relevant to sepsis, viral infections (e.g., COVID-19), and chronic inflammatory diseases (e.g., Duchenne Muscular Dystrophy, Parkinson's Disease).
• Selinexor can enhance bone marrow transplant outcomes.

Conclusions:

• Selinexor presents a dual therapeutic profile, offering potential in both cancer and inflammatory disease management.
• Careful management of side effects through dose optimization and monitoring is crucial.
• Further extensive research is required to validate long-term safety and efficacy for diverse clinical applications.